4.7 Article

Impulse Control Disorders in Parkinson Disease: A Multicenter Case-Control Study

期刊

ANNALS OF NEUROLOGY
卷 69, 期 6, 页码 986-996

出版社

WILEY
DOI: 10.1002/ana.22356

关键词

-

资金

  1. Boehringer Ingelheim
  2. Lundbeck
  3. Motac
  4. Mohegan Sun Casino
  5. National Center for Responsible Gaming
  6. Merck Serono
  7. Teva
  8. General Electric
  9. Michael J. Fox Foundation
  10. Allergan
  11. Osmotica
  12. Biogen
  13. Kyowa
  14. Neurologix
  15. Novartis
  16. Synosia
  17. Biovail
  18. Ceregene
  19. Eisai
  20. Medtronic
  21. Prestwick
  22. Solvay
  23. Taro
  24. Ontario Problem Gambling Research Centre
  25. Michael J. Fox Foundation for Parkinson's Research

向作者/读者索取更多资源

Objective: To assess factors associated with impulse control disorders (ICDs) in Parkinson disease (PD) using a multicenter case-control design. Methods: Patients enrolled in the DOMINION study, a multicenter study assessing the cross-sectional frequency of ICDs in PD, were eligible to participate in the case-control study. PD patients with and without an ICD (n = 282 each) (compulsive gambling, buying, sexual behavior, and eating) were matched individually on age, gender, and dopamine agonist treatment. Subjects were assessed with a comprehensive neurological, psychiatric, and cognitive assessment battery. Results: ICD patients reported more functional impairment (p < 0.001); greater depressive (p < 0.0001), state (p < 0.0001), and trait (p < 0.0001) anxiety; greater obsessive-compulsive symptoms (p < 0.0001); higher novelty-seeking (p < 0.001) and impulsivity (p < 0.001); and differences in reward preference reflecting greater choice impulsivity (p < 0.05). Patients with multiple ICDs had greater dyskinesia scores compared to those with single ICDs. Interpretation: ICDs in PD are associated with multiple psychiatric and cognitive impairments, including affective and anxiety symptoms, as well as elevated obsessionality, novelty seeking, and impulsivity. These results highlight the importance of assessing multiple mental health domains in individuals with PD and ICDs, and suggest possible pathophysiological mechanisms and risk indicators for these disorders. ANN NEUROL 2011;69:986-996

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Letter Clinical Neurology

CBD diagnostic criteria: exclusions as important as inclusions

Irene Litvan, Anthony E. Lang, Melissa Armstrong

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

Plasma phosphorylated tau181 predicts cognitive and functional decline

Thomas F. Tropea, Teresa Waligorska, Sharon X. Xie, Ilya M. Nasrallah, Katheryn A. Q. Cousins, John Q. Trojanowski, Murray Grossman, David J. Irwin, Daniel Weintraub, Edward B. Lee, David A. Wolk, Alice S. Chen-Plotkin, Leslie M. Shaw

Summary: The objective of this study was to determine if plasma tau phosphorylated at threonine 181 (p-tau181) can distinguish Alzheimer's disease (AD) from normal cognition (NC) in adults, predict cognitive and functional decline, and validate findings in an external cohort. The results showed that plasma p-tau181 can accurately differentiate AD pathology from NC, and higher levels of p-tau181 are associated with faster cognitive and functional decline.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Clinical Neurology

Pathological combinations in neurodegenerative disease are heterogeneous and disease-associated

John L. Robinson, Sharon X. Xie, Daniel R. Baer, EunRan Suh, Vivianna M. Van Deerlin, Nicholas J. Loh, David J. Irwin, Corey T. McMillan, David A. Wolk, Alice Chen-Plotkin, Daniel Weintraub, Theresa Schuck, Virginia M. Y. Lee, John Q. Trojanowski, Edward B. Lee

Summary: In this retrospective study, the incidence of 10 pathologies in neurodegenerative disease (ND) and normal aging was examined, with up to seven pathologies observed concurrently resulting in 161 different combinations. The presence of multiple additive pathologies was associated with factors such as longer disease duration, clinical dementia, older age, and APOE e4 status.
Article Clinical Neurology

Distinguishing functional from primary tics: a study of expert video assessments

Antigony Rigas, Tina Mainka, Tamara Pringsheim, Alexander Muenchau, Irene Malaty, Yulia Worbe, Andrea E. Cavanna, Andrew John Lees, Anthony E. Lang, Davide Martino, Christos Ganos

Summary: This study revealed that the diagnostic distinction between primary and functional tics is often difficult, even for expert clinicians, in the absence of clinical information.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2023)

Article Clinical Neurology

The Lessebo Effect in Disease Modification Trials in Parkinson's Disease

Tiago A. Mestre, Michael P. McDermott, Raquel Lobo, Joaquim J. Ferreira, Anthony E. E. Lang

Summary: This study evaluated the "lessebo effect" in disease modification trials in Parkinson's disease and found that it did not exist in these trials. However, the use of placebo instead of an active comparator was a limitation. Prospective measurement of expectation of benefit could help assess the various impacts of placebo use.

MOVEMENT DISORDERS (2023)

Letter Clinical Neurology

Targeting alpha-Synuclein: A Further Viewpoint

Anthony E. Lang

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies

Danielle S. Abraham, Thanh Phuong Pham Nguyen, Leah J. Blank, Dylan Thibault, Shelly L. Gray, Sean Hennessy, Charles E. Leonard, Daniel Weintraub, Allison W. Willis

Summary: This study examined the differential prescribing patterns between new and established treatments for common neurological conditions. Using data from a national sample of US commercially insured adults from 2005-2019, the study compared new users of recently approved medications for three conditions: diabetic peripheral neuropathy, Parkinson disease psychosis, and epilepsy. The results showed that newer medications were more frequently prescribed to individuals with prior treatment, suggesting potential bias in comparative effectiveness and safety studies. The study emphasizes the importance of reporting propensity score non-overlap in comparative studies involving newer medications and suggests methodological approaches to address channeling bias.

NEUROTHERAPEUTICS (2023)

Article Clinical Neurology

Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease

Katheryn A. Q. Cousins, David J. Irwin, Alice Chen-Plotkin, Leslie M. Shaw, Sanaz Arezoumandan, Edward B. Lee, David A. Wolk, Daniel Weintraub, Meredith Spindler, Andres Deik, Murray Grossman, Thomas F. Tropea

Summary: This study found that plasma GFAP may be sensitive to concomitant AD pathology in LBSD, especially accumulation of beta-amyloid plaques.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Article Neurosciences

LRRK2 and GBA1 variant carriers have higher urinary bis(monacylglycerol) phosphate concentrations in PPMI cohorts

Kalpana M. Merchant, Tanya Simuni, Janel Fedler, Chelsea Caspell-Garcia, Michael Brumm, Kelly N. H. Nudelman, Elizabeth Tengstrandt, Frank Hsieh, Roy N. Alcalay, Christopher Coffey, Lana Chahine, Tatiana Foroud, Andrew Singleton, Daniel Weintraub, Samantha Hutten, Todd Sherer, Brit Mollenhauer, Andrew Siderowf, Caroline Tanner, Ken Marek

Summary: We quantified concentrations of three isoforms of BMP in different cohorts of Parkinson's disease patients and found that LRRK2 and GBA1 gene mutations were associated with elevated BMP levels. However, BMP is not a prognostic or disease progression biomarker.

NPJ PARKINSONS DISEASE (2023)

Article Clinical Neurology

Impact of the Dopamine System on Long-Term Cognitive Impairment in Parkinson Disease: An Exploratory Study

Daniel Weintraub, Marina Picillo, Hyunkeun Ryan Cho, Chelsea Caspell-Garcia, Cornelis Blauwendraat, Ethan G. Brown, Lana M. Chahine, Christopher S. Coffey, Roseanne D. Dobkin, Tatiana Foroud, Doug Galasko, Karl Kieburtz, Kenneth Marek, Kalpana Merchant, Brit Mollenhauer, Kathleen L. Poston, Tanya Simuni, Andrew Siderowf, Andrew Singleton, John Seibyl, Caroline M. Tanner

Summary: This study used data from a multi-site, international, prospective cohort study to investigate the impact of dopamine system-related biomarkers on cognitive impairment in Parkinson's disease. The results showed that alterations in the dopamine system were associated with the development of cognitive impairment in Parkinson's disease. If confirmed causative, these findings suggest that the dopamine system is instrumental to cognitive health status throughout the disease course.

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

Article Clinical Neurology

Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy

Daniel G. Di Luca, Carolina Ramirez-Gomez, Jurgen Germann, Brendan Santyr, Alexandre Boutet, Luka Milosevic, Anthony E. Lang, Suneil K. Kalia, Andres M. Lozano, Alfonso Fasano

Summary: This study aimed to evaluate the safety and efficacy of deep brain stimulation on the globus pallidus pars interna and externa in MSA-P patients. The surgery did not result in major complications, but did not provide significant clinical benefit as measured by MDS-UPDRS III.

MOVEMENT DISORDERS (2023)

Article Clinical Neurology

Safety, tolerability, and preliminary efficacy of SYN120, a dual 5-HT6/5-HT2A antagonist, for the treatment of Parkinson disease dementia: A randomized, controlled, proof-of-concept trial

Hubert H. Fernandez, Daniel Weintraub, Eric Macklin, Irene Litvan, Michael A. Schwarzschild, Jamie Eberling, Aleksandar Videnovic, Christopher J. Kenney

Summary: In patients with Parkinson disease dementia (PDD), SYN120 did not improve cognition significantly but showed potential benefits in cognitive activities of daily living and apathy.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

Potentially inappropriate medications in older adults with Parkinson disease before and after hospitalization for injury

Thanh Phuong Pham Nguyen, Shelly L. Gray, Craig W. Newcomb, Qing Liu, Ali G. Hamedani, Daniel Weintraub, Sean Hennessy, Allison W. Willis

Summary: This study found that there were no significant differences in medication prescriptions between Parkinson disease (PD) patients hospitalized for serious injury and those hospitalized for other reasons, indicating a missed opportunity to deprescribe high-risk medications during care transitions.

PARKINSONISM & RELATED DISORDERS (2023)

Article Clinical Neurology

Estimation of Ambulation and Survival in Neurodegeneration with Brain Iron Accumulation Disorders

Elahe Amini, Mohammad Rohani, Anthony E. Lang, Zahra Azad, Seyed Amir Hassan Habibi, Afagh Alavi, Gholamali Shahidi, Maziar Emamikhah, Ahmad Chitsaz

Summary: Among 122 genetically confirmed NBIA patients, KRS had the best survival and longest preservation of ambulation ability, while classical PKAN and MPAN patients showed similar progression patterns in loss of ambulation ability, with MPAN patients having a slower progression to death. Spasticity was identified as the most significant factor associated with death.

MOVEMENT DISORDERS CLINICAL PRACTICE (2023)

暂无数据